Anakinra in COVID-19-How to Interpret Elevations of Serum Liver Enzymes: Comment on the Article by Navarro-Millán et al.

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2021)

We read with interest the study by Navarro-Millàn and colleagues on the use of anakinra in severe COVID-19 patients with acute respiratory insufficiency and hyper-inflammation (1). The Authors tried to identify the clinical phenotype that is most likely to benefit from anakinra treatment, in order to maximize utility and not to expose patients to unnecessary risks related to immunosuppression.

Keyphrases

coronavirus disease
sars cov
end stage renal disease
newly diagnosed
oxidative stress
ejection fraction
prognostic factors
peritoneal dialysis
early onset
patient reported outcomes
risk assessment
climate change
combination therapy
drug induced
patient reported
replacement therapy
smoking cessation